Shilpa Medicare’s USFDA Inspection Analyzed
Shilpa Medicare recently finished a ten-day inspection by the US Food and Drug Administration (USFDA) at their facility in Jadcherla, Telangana, India. The inspection, completed on November 21, 2025, resulted in an FDA Form 483 being issued. Importantly, none of the observations were repeated, indicating consistent quality control.
Key Points
- USFDA inspection completed, Form 483 issued at Jadcherla.
- No repeat observations, highlighting operational improvement & consistency.
- Facility produces sterile injectables, tablets, and capsules globally.
- US sales are minimal (under 1%) of total business volume.
- Approved by key regulators: EMA, Canada, Brazil, Australia.
- Consistent quality management aligns with global market demands.
This facility is designed to make a variety of medicines – including injectable drugs, tablets, and capsules. These products are shipped to customers all over the world, including the United States, Europe, and other countries. The US market accounts for a very small part of Shilpa Medicare’s total sales.
The USFDA inspections are important because they make sure companies are following rules for making medicines safely. The fact that this facility didn’t have any repeated problems is a good sign. Shilpa Medicare is approved by important regulatory bodies, allowing them to sell their products in many different countries.
Shilpa Medicare’s focus on compliance, combined with approvals from diverse global regulators, positions the company for continued international market expansion.
“A clean USFDA inspection demonstrates Shilpa Medicare’s commitment to meeting the highest quality standards worldwide.”
